Neurological sequelae of cancer immunotherapies and targeted therapies

The Lancet Oncology

Volumn 17, Issue 12, 2016, Pages e529-e541

  Wick, Wolfgang ^a,b   Hertenstein, Anne ^a,b   Platten, Michael ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLINATUMOMAB; BORTEZOMIB; BUSULFAN; CALCIUM; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DABRAFENIB; DASATINIB; ENZALUTAMIDE; EVEROLIMUS; FLUOROURACIL; GEFITINIB; IFOSFAMIDE; IPILIMUMAB; METHOTREXATE; NITROSOUREA; PANITUMUMAB; PROCARBAZINE; RIDAFOROLIMUS; RITUXIMAB; TEMOZOLOMIDE; TEMSIROLIMUS; UNINDEXED DRUG; VASCULOTROPIN; VEMURAFENIB;

ACUTE BRAIN DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; CALCIUM HOMEOSTASIS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM INFECTION; DRUG MECHANISM; DRUG MEGADOSE; FATALITY; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOPHYSITIS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MORBIDITY; MYOPATHY; NEUROLOGICAL COMPLICATION; NEUROMUSCULAR JUNCTION DISORDER; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SEIZURE; SPINAL CORD DISEASE; VASOPRESSIN RELEASE; ADVERSE EFFECTS; BRAIN DISEASES; CEREBELLAR DISEASES; IMMUNOTHERAPY; LEUKOENCEPHALOPATHIES; MOLECULARLY TARGETED THERAPY; NEOPLASMS; NERVOUS SYSTEM DISEASES; SEIZURES;

BRAIN DISEASES; CEREBELLAR DISEASES; HUMANS; IMMUNOTHERAPY; LEUKOENCEPHALOPATHIES; MOLECULAR TARGETED THERAPY; NEOPLASMS; NERVOUS SYSTEM DISEASES; SEIZURES;

EID: 85003696217     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30571-X     Document Type: Review

References (75)

1. 1 Wefel, JS, Lenzi, R, Theriault, R, Buzdar, AU, Cruickshank, S, Meyers, CA, ‘Chemobrain’ in breast carcinoma? A prologue. Cancer 101 (2004), 466–475.
2. 2 Holmes, D, Trying to unravel the mysteries of chemobrain. Lancet Neurol 12 (2013), 533–534.
3. 3 Deprez, S, Amant, F, Smeets, A, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol 30 (2012), 274–281.
4. 4 Nokia, MS, Anderson, ML, Shors, TJ, Chemotherapy disrupts learning, neurogenesis and theta activity in the adult brain. Eur J Neurosci 36 (2012), 3521–3530.
5. 5 Pirl, WF, Siegel, GI, Goode, MJ, Smith, MR, Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psychooncology 11 (2002), 518–523.
6. 6 von Geldern, G, Pardo, CA, Calabresi, PA, Newsome, SD, PML-IRIS in a patient treated with brentuximab. Neurology 79 (2012), 2075–2077.
7. 7 Carson, KR, Newsome, SD, Kim, EJ, et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 120 (2014), 2464–2471.
8. 8 Coussens, LM, Werb, Z, Inflammation and cancer. Nature 420 (2002), 860–867.
9. 9 Zoller, B, Ji, J, Sundquist, J, Sundquist, K, Risk of haemorrhagic and ischaemic stroke in patients with cancer: a nationwide follow-up study from Sweden. Eur J Cancer 48 (2012), 1875–1883.
10. 10 Dalmau, J, Rosenfeld, MR, Paraneoplastic syndromes of the CNS. Lancet Neurol 7 (2008), 327–340.
11. 11 Eiden, AM, Zhang, S, Gary, JM, Simmons, JK, Mock, BA, Molecular pathways: increased susceptibility to infection is a complication of mTOR inhibitor use in cancer therapy. Clin Cancer Res 22 (2016), 277–283.
12. 12 PDQ Supportive and Palliative Care Editorial Board. PDQ cancer information summaries: fatigue, 2014, National Cancer Institute, Bethesda.
13. 13 Smith, EM, Pang, H, Cirrincione, C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309 (2013), 1359–1367.
14. 14 Albers, JW, Chaudhry, V, Cavaletti, G, Donehower, RC, Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev, 3, 2014 CD005228.
15. 15 Platten, M, Opitz, CA, Kohlhof, P, Hegenbart, U, Ho, AD, Wick, W, Painful neuropathy due to intraneural leukemic spread in a patient with acute myeloid leukemia. Neurology, 69, 2007, 707.
16. 16 Topp, MS, Gokbuget, N, Stein, AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16 (2015), 57–66.
17. 17 Topp, MS, Gokbuget, N, Zugmaier, G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 32 (2014), 4134–4140.
18. 18 Maude, SL, Frey, N, Shaw, PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371 (2014), 1507–1517.
19. 19 Lee, DW, Kochenderfer, JN, Stetler-Stevenson, M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385 (2015), 517–528.
20. 20 Topp, MS, Gokbuget, N, Zugmaier, G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120 (2012), 5185–5187.
21. 21 Topp, MS, Kufer, P, Gokbuget, N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29 (2011), 2493–2498.
22. 22 Bargou, R, Leo, E, Zugmaier, G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321 (2008), 974–977.
23. 23 Ribera, JM, Ferrer, A, Ribera, J, Genesca, E, Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia. Onco Targets Ther 8 (2015), 1567–1574.
24. 24 Morgan, RA, Chinnasamy, N, Abate-Daga, D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36 (2013), 133–151.
25. 25 Kochenderfer, JN, Dudley, ME, Feldman, SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119 (2012), 2709–2720.
26. 26 Fathpour, P, Obad, N, Espedal, H, et al. Bevacizumab treatment for human glioblastoma. Can it induce cognitive impairment?. Neuro Oncol 16 (2014), 754–756.
27. 27 Goldhirsch, A, Gelber, RD, Piccart-Gebhart, MJ, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382 (2013), 1021–1028.
28. 28 Slamon, D, Eiermann, W, Robert, N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365 (2011), 1273–1283.
29. 29 Balduzzi, S, Mantarro, S, Guarneri, V, et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev, 6, 2014 CD006242.
30. 30 Scher, HI, Fizazi, K, Saad, F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 (2012), 1187–1197.
31. 31 Patel, SP, Woodman, SE, Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des Devel Ther 5 (2011), 489–495.
32. 32 Bot, I, Blank, CU, Boogerd, W, Brandsma, D, Neurological immune-related adverse events of ipilimumab. Pract Neurol 13 (2013), 278–280.
33. 33 Araujo, PB, Coelho, MC, Arruda, M, Gadelha, MR, Neto, LV, Ipilimumab-induced hypophysitis: review of the literature. J Endocrinol Invest 38 (2015), 1159–1166.
34. 34 Eggermont, AM, Chiarion-Sileni, V, Grob, JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16 (2015), 522–530.
35. 35 Iwama, S, De Remigis, A, Callahan, MK, Slovin, SF, Wolchok, JD, Caturegli, P, Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med, 6, 2014, 230ra45.
36. 36 Min, L, Hodi, FS, Giobbie-Hurder, A, et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res 21 (2015), 749–755.
37. 37 Naidoo, J, Page, DB, Li, BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26 (2015), 2375–2391.
38. 38 Shirai, T, Sano, T, Kamijo, F, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 46 (2016), 86–88.
39. 39 Loochtan, AI, Nickolich, MS, Hobson-Webb, LD, Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 52 (2015), 307–308.
40. 40 Borghaei, H, Paz-Ares, L, Horn, L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
41. 41 Maurice, C, Schneider, R, Kiehl, TR, et al. Subacute CNS demyelination after treatment with nivolumab for melanoma. Cancer Immunol Res 3 (2015), 1299–1302.
42. 42 Kyi, C, Carvajal, RD, Wolchok, JD, Postow, MA, Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer, 2, 2014, 35.
43. 43 Weber, JS, Yang, JC, Atkins, MB, Disis, ML, Toxicities of immunotherapy for the practitioner. J Clin Oncol 33 (2015), 2092–2099.
44. 44 Bennett, CL, Pharmacovigilance and PML in the oncology setting. Cleve Clin J Med 78:suppl 2 (2011), S13–S17.
45. 45 Pavlovic, D, Patera, AC, Nyberg, F, Gerber, M, Liu M; Progressive Multifocal Leukeoncephalopathy Consortium. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord 8 (2015), 255–273.
46. 46 Carson, KR, Focosi, D, Major, EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10 (2009), 816–824.
47. 47 Jelcic, I, Jelcic, I, Kempf, C, et al. Mechanisms of immune escape in central nervous system infection with neurotropic JC virus variant. Ann Neurol 79 (2016), 404–418.
48. 48 Fugate, JE, Rabinstein, AA, Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol 14 (2015), 914–925.
49. 49 Mir, O, Ropert, S, Alexandre, J, Goldwasser, F, Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol 20 (2009), 967–970.
50. 50 Dirix, LY, Rutsaert, R, Arterial hypertension induced by vascular endothelial growth factor interfering agents: mechanisms and management. Belg J Med Oncol 4 (2010), 159–167.
51. 51 Wick, A, Schafer, N, Dorner, N, et al. Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome. J Neurooncol 97 (2010), 157–158.
52. 52 Baselga, J, Campone, M, Piccart, M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366 (2012), 520–529.
53. 53 Wilgenhof, S, Neyns, B, Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol 22 (2011), 991–993.
54. 54 Liao, B, Shroff, S, Kamiya-Matsuoka, C, Tummala, S, Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16 (2014), 589–593.
55. 55 Gaudy-Marqueste, C, Monestier, S, Franques, J, Cantais, E, Richard, MA, Grob, JJ, A severe case of ipilimumab-induced Guillain-Barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother 36 (2013), 77–78.
56. 56 Bhatia, S, Huber, BR, Upton, MP, Thompson, JA, Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother 32 (2009), 203–205.
57. 57 Tarhini, A, Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo), 2013, 2013, 857519.
58. 58 Maur, M, Tomasello, C, Frassoldati, A, Dieci, MV, Barbieri, E, Conte, P, Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol 30 (2012), e76–e78.
59. 59 Andrews, S, Holden, R, Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res 4 (2012), 299–307.
60. 60 Weber, JS, Kahler, KC, Hauschild, A, Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30 (2012), 2691–2697.
61. 61 O'Kane, GM, Lyons, TG, Colleran, GC, et al. Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma. Oncol Res Treat 37 (2014), 757–760.
62. 62 Crosson, JN, Laird, PW, Debiec, M, Bergstrom, CS, Lawson, DH, Yeh, S, Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma. J Immunother 38 (2015), 80–84.
63. 63 Johnson, DC, Corthals, SL, Walker, BA, et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 29 (2011), 797–804.
64. 64 Dimopoulos, MA, Moreau, P, Palumbo, A, ENDEAVOR Investigators, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17 (2016), 27–38.
65. 65 Moreau, P, Masszi, T, Grzasko, N, et al. Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374 (2016), 1621–1634.
66. 66 Broyl, A, Corthals, SL, Jongen, JL, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 11 (2010), 1057–1065.
67. 67 Blumenthal, GM, Scher, NS, Cortazar, P, et al. First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Clin Cancer Res 19 (2013), 4911–4916.
68. 68 Younes, A, Bartlett, NL, Leonard, JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363 (2010), 1812–1821.
69. 69 Younes, A, Gopal, AK, Smith, SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30 (2012), 2183–2189.
70. 70 Forero-Torres, A, Holkova, B, Goldschmidt, J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood 126 (2015), 2798–2804.
71. 71 Fanale, MA, Forero-Torres, A, Rosenblatt, JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 18 (2012), 248–255.
72. 72 Wick, W, Fricke, H, Junge, K, et al. A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma. Clin Cancer Res 20 (2014), 6304–6313.
73. 73 Twyman-Saint Victor, C, Rech, AJ, Maity, A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520 (2015), 373–377.
74. 74 Gray, J, Haura, E, Update on third-generation EGFR tyrosine kinase inhibitors. Transl Lung Cancer Res 3 (2014), 360–362.
75. 75 Nayak, L, DeAngelis, L, Wen, P, et al. The Neurologic Assessment in Neuro-Oncology (NANO) Scale: a tool to assess neurologic function for integration in the Radiologic Assessment in Neuro-Oncology (RANO) Criteria (S22.005). Neurology, 82(suppl 10), 2015 S22.005.